MNKD
NASDAQ · Biotechnology
Mannkind Corp
$3.94
+0.01 (+0.25%)
Open$3.94
Previous Close$3.93
Day High$3.96
Day Low$3.92
52W High$6.51
52W Low$2.23
Volume—
Avg Volume5.20M
Market Cap1.22B
P/E Ratio—
EPS$-0.08
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+702.3% upside
Current
$3.94
$3.94
Target
$31.61
$31.61
$20.51
$31.61 avg
$34.61
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 345.88M | 227.88M | 248.98M |
| Net Income | 5.82M | 3.45M | -49,454,944 |
| Profit Margin | 1.7% | 1.6% | -19.9% |
| EBITDA | 42.40M | 26.54M | -82,218,351 |
| Free Cash Flow | — | — | -29,596,680 |
| Rev Growth | +51.8% | +51.8% | +22.2% |
| Debt/Equity | 1.64 | 1.64 | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |